Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A combination therapy used primarily for treating polycystic ovary syndrome (PCOS). This combination addresses multiple aspects of PCOS: - **Cyproterone acetate**: A steroidal antiandrogen that blocks androgen production in the ovaries, reducing hirsutism and acne - **Ethinylestradiol**: An estrogen that enhances cyproterone's effects by further reducing androgen levels and regularizing menstrual cycles - **Metformin**: An insulin sensitizer that improves metabolic parameters and may further suppress hyperandrogenemia Clinical studies show this combination provides better and faster decreases in testosterone levels and free androgen index compared to cyproterone acetate/ethinylestradiol alone, without deteriorating anthropometric indices or insulin sensitivity.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cyproterone acetate + ethinylestradiol + metformin.